Changes of central noradrenaline transporter availability in immunotherapy-naïve multiple sclerosis patients.
Adult
Brain
/ diagnostic imaging
Carbon Radioisotopes
/ metabolism
Depression
/ psychology
Disability Evaluation
Fatigue
/ psychology
Female
Humans
Immunotherapy
Magnetic Resonance Imaging
/ methods
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting
/ diagnostic imaging
Norepinephrine
/ metabolism
Norepinephrine Plasma Membrane Transport Proteins
/ metabolism
Positron-Emission Tomography
/ methods
Psychiatric Status Rating Scales
Reboxetine
/ metabolism
Young Adult
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
04 09 2020
04 09 2020
Historique:
received:
10
12
2019
accepted:
17
07
2020
entrez:
5
9
2020
pubmed:
6
9
2020
medline:
20
3
2021
Statut:
epublish
Résumé
The neurotransmitter noradrenaline (NA) mediates arousal, attention and mood, and exerts anti-inflammatory and neuroprotective effects. Alterations of monoamine signalling were reported in multiple sclerosis (MS) and psychiatric illness and may account for the high prevalence of comorbid depression and fatigue in MS patients. We assessed central noradrenaline transporter (NAT) availability using positron emission tomography (PET) and the NAT selective radiotracer S,S-[
Identifiants
pubmed: 32887904
doi: 10.1038/s41598-020-70732-5
pii: 10.1038/s41598-020-70732-5
pmc: PMC7474089
doi:
Substances chimiques
Carbon Radioisotopes
0
Carbon-11
0
Norepinephrine Plasma Membrane Transport Proteins
0
O-methyl reboxetine
0
Reboxetine
947S0YZ36I
Norepinephrine
X4W3ENH1CV
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14651Références
Krupp, L. B., Alvarez, L. A., LaRocca, N. G. & Scheinberg, L. C. Fatigue in multiple sclerosis. Arch. Neurol. 45, 435–437. https://doi.org/10.1001/archneur.1988.00520280085020 (1988).
doi: 10.1001/archneur.1988.00520280085020
pubmed: 3355400
Patten, S. B., Beck, C. A., Williams, J. V. A., Barbui, C. & Metz, L. M. Major depression in multiple sclerosis. A population-based perspective. Neurology 61, 1524–1527. https://doi.org/10.1212/01.wnl.0000095964.34294.b4 (2003).
doi: 10.1212/01.wnl.0000095964.34294.b4
pubmed: 14663036
von Bismarck, O. et al. Treatment choices and neuropsychological symptoms of a large cohort of early MS. Neurology Neuroimmunol. Neuroinflammat. 5, 446. https://doi.org/10.1212/NXI.0000000000000446 (2018).
doi: 10.1212/NXI.0000000000000446
Chiaravalloti, N. D. & DeLuca, J. Cognitive impairment in multiple sclerosis. The Lancet. Neurology 7, 1139–1151. https://doi.org/10.1016/S1474-4422(08)70259-X (2008).
doi: 10.1016/S1474-4422(08)70259-X
pubmed: 19007738
Berridge, C. W. & Waterhouse, B. D. The locus coeruleus-noradrenergic system. Modulation of behavioral state and state-dependent cognitive processes. Brain Res. Rev. 42, 33–84 (2003).
doi: 10.1016/S0165-0173(03)00143-7
Simonini, M. V. et al. Increasing CNS noradrenaline reduces EAE severity. J. Neuroimmune Pharmacol. 5, 252–259. https://doi.org/10.1007/s11481-009-9182-2 (2010).
doi: 10.1007/s11481-009-9182-2
pubmed: 19957206
Gulyás, B. et al. The norepinephrine transporter (NET) radioligand (S, S)-18FFMeNER-D2 shows significant decreases in NET density in the human brain in Alzheimer’s disease: a post-mortem autoradiographic study. Neurochem. Int. 56, 789–798. https://doi.org/10.1016/j.neuint.2010.03.001 (2010).
doi: 10.1016/j.neuint.2010.03.001
pubmed: 20211213
Remy, P., Doder, M., Lees, A., Turjanski, N. & Brooks, D. Depression in Parkinson’s disease. Loss of dopamine and noradrenaline innervation in the limbic system. Brain128, 1314–1322. https://doi.org/10.1093/brain/awh445 (2005).
doi: 10.1093/brain/awh445
pubmed: 15716302
Moriguchi, S. et al. Norepinephrine transporter in major depressive disorder. A PET study. Am. J. Psychiat. 174, 36–41. https://doi.org/10.1176/appi.ajp.2016.15101334 (2017).
doi: 10.1176/appi.ajp.2016.15101334
pubmed: 27631962
Goddard, A. W. et al. Current perspectives of the roles of the central norepinephrine system in anxiety and depression. Depress. Anxiety 27, 339–350. https://doi.org/10.1002/da.20642 (2010).
doi: 10.1002/da.20642
pubmed: 19960531
Vanicek, T. et al. The norepinephrine transporter in attention-deficit/hyperactivity disorder investigated with positron emission tomography. JAMA Psychiatry 71, 1340–1349. https://doi.org/10.1001/jamapsychiatry.2014.1226 (2014).
doi: 10.1001/jamapsychiatry.2014.1226
pubmed: 25338091
pmcid: 4699255
Feinstein, D. L., Kalinin, S. & Braun, D. Causes, consequences, and cures for neuroinflammation mediated via the locus coeruleus. Noradrenergic signaling system. J. Neurochem. 139, 154–178. https://doi.org/10.1111/jnc.13447 (2016).
doi: 10.1111/jnc.13447
pubmed: 26968403
Frohman, E. M., Vayuvegula, B., van den Noort, S. & Gupta, S. Norepinephrine inhibits gamma-interferon-induced MHC class II (Ia) antigen expression on cultured brain astrocytes. J. Neuroimmunol. 17, 89–101. https://doi.org/10.1016/0165-5728(88)90017-3 (1988).
doi: 10.1016/0165-5728(88)90017-3
pubmed: 2826540
Heneka, M. T. et al. Locus ceruleus controls Alzheimer’s disease pathology by modulating microglial functions through norepinephrine. Proc. Natl. Acad. Sci. USA 107, 6058–6063. https://doi.org/10.1073/pnas.0909586107 (2010).
doi: 10.1073/pnas.0909586107
pubmed: 20231476
Patel, N. J., Chen, M. J. & Russo-Neustadt, A. A. Norepinephrine and nitric oxide promote cell survival signaling in hippocampal neurons. Eur. J. Pharmacol. 633, 1–9. https://doi.org/10.1016/j.ejphar.2010.01.012 (2010).
doi: 10.1016/j.ejphar.2010.01.012
pubmed: 20149790
Polak, P. E., Kalinin, S. & Feinstein, D. L. Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain 134, 665–677. https://doi.org/10.1093/brain/awq362 (2011).
doi: 10.1093/brain/awq362
pubmed: 21297130
pmcid: 3105488
Markianos, M. et al. Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis. J. Neurochem. 108, 158–164. https://doi.org/10.1111/j.1471-4159.2008.05750.x (2009).
doi: 10.1111/j.1471-4159.2008.05750.x
pubmed: 19014375
Benarroch, E. E. Monoamine transporters. Structure, regulation, and clinical implications. Neurology 81, 761–768. https://doi.org/10.1212/WNL.0b013e3182a1ab4a (2013).
doi: 10.1212/WNL.0b013e3182a1ab4a
pubmed: 23902707
Hesse, S. et al. Central noradrenaline transporter availability in highly obese, non-depressed individuals. Eur. J. Nucl. Med. Mol. Imag. 44, 1056–1064. https://doi.org/10.1007/s00259-016-3590-3 (2017).
doi: 10.1007/s00259-016-3590-3
Gallezot, J.-D. et al. Evaluation of (11)CMRB for assessment of occupancy of norepinephrine transporters. Studies with atomoxetine in non-human primates. NeuroImage 56, 268–279. https://doi.org/10.1016/j.neuroimage.2010.09.040 (2011).
doi: 10.1016/j.neuroimage.2010.09.040
pubmed: 20869448
Park, E. et al. (11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas. Eur. J. Nucl. Med. Mol. Imag. 42, 1081–1092. https://doi.org/10.1007/s00259-015-3043-4 (2015).
doi: 10.1007/s00259-015-3043-4
Airas, L., Rissanen, E. & Rinne, J. Imaging of microglial activation in MS using PET: Research use and potential future clinical application. Mult. Scleros. 23, 496–504. https://doi.org/10.1177/1352458516674568 (2017).
doi: 10.1177/1352458516674568
Stankoff, B. et al. Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using methyl-
doi: 10.1002/ana.22320
pubmed: 21337603
Pietroboni, A. M. et al. Amyloid PET as a marker of normal-appearing white matter early damage in multiple sclerosis: correlation with CSF β-amyloid levels and brain volumes. Eur. J. Nucl. Med. Mol. Imag. 46, 280–287. https://doi.org/10.1007/s00259-018-4182-1 (2019).
doi: 10.1007/s00259-018-4182-1
Faria, D. P., Copray, S., Buchpiguel, C., Dierckx, R. & deVries, E. PET imaging in multiple sclerosis. J. Neuroimmune Pharmacol. 9, 468–482. https://doi.org/10.1007/s11481-014-9544-2 (2014).
doi: 10.1007/s11481-014-9544-2
Högel, H., Rissanen, E., Vuorimaa, A. & Airas, L. Positron emission tomography imaging in evaluation of MS pathology in vivo. Mult. Scleros. 24, 1399–1412. https://doi.org/10.1177/1352458518791680 (2018).
doi: 10.1177/1352458518791680
Polak, P. E., Lin, S. X., Pelligrino, D. & Feinstein, D. L. The blood-brain barrier-permeable catechol-O-methyltransferase inhibitor dinitrocatechol suppresses experimental autoimmune encephalomyelitis. J. Neuroimmunol. 276, 135–141. https://doi.org/10.1016/j.jneuroim.2014.09.004 (2014).
doi: 10.1016/j.jneuroim.2014.09.004
pubmed: 25242632
Zoukos, Y., Leonard, J. P., Thomaides, T., Thompson, A. J. & Cuzner, M. L. beta-Adrenergic receptor density and function of peripheral blood mononuclear cells are increased in multiple sclerosis: a regulatory role for cortisol and interleukin-1. Ann. Neurol. 31, 657–662. https://doi.org/10.1002/ana.410310614 (1992).
doi: 10.1002/ana.410310614
pubmed: 1325138
Boyko, A., Melnikov, M., Zhetishev, R. & Pashenkov, M. The role of biogenic amines in the regulation of interaction between the immune and nervous systems in multiple sclerosis. Neuroimmunomodulation 23, 217–223. https://doi.org/10.1159/000449167 (2016).
doi: 10.1159/000449167
pubmed: 27710965
Hesse, S. et al. Altered serotonin transporter availability in patients with multiple sclerosis. Eur. J. Nucl. Med. Mol. Imag. 41, 827–835. https://doi.org/10.1007/s00259-013-2636-z (2014).
doi: 10.1007/s00259-013-2636-z
Cosentino, M. et al. Catecholamine production and tyrosine hydroxylase expression in peripheral blood mononuclear cells from multiple sclerosis patients: effect of cell stimulation and possible relevance for activation-induced apoptosis. J. Neuroimmunol. 133, 233–240 (2002).
doi: 10.1016/S0165-5728(02)00372-7
Rajda, C. et al. The norepinephrine level is decreased in the lymphocytes of long-term interferon-beta-treated multiple sclerosis patients. Multi. Scleros. 12, 265–270. https://doi.org/10.1191/135248506ms1269oa (2006).
doi: 10.1191/135248506ms1269oa
Kaneko, Y. S. et al. Peripheral injection of lipopolysaccharide enhances expression of inflammatory cytokines in murine locus coeruleus. Possible role of increased norepinephrine turnover. J. Neurochem. 94, 393–404. https://doi.org/10.1111/j.1471-4159.2005.03209.x (2005).
doi: 10.1111/j.1471-4159.2005.03209.x
pubmed: 15998290
Then Bergh, F., Kümpfel, T., Trenkwalder, C., Rupprecht, R. & Holsboer, F. Dysregulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of MS. Neurology 53, 772. https://doi.org/10.1212/WNL.53.4.772 (1999).
doi: 10.1212/WNL.53.4.772
pubmed: 10489039
Heesen, C., Gold, S. M., Raji, A., Wiedemann, K. & Schulz, K.-H. Cognitive impairment correlates with hypothalamo-pituitary-adrenal axis dysregulation in multiple sclerosis. Psychoneuroendocrinology 27, 505–517 (2002).
doi: 10.1016/S0306-4530(01)00071-3
Schinke, C. et al. Central noradrenaline transporter availability is linked with HPA axis responsiveness and copeptin in human obesity and non-obese controls. Stress 22, 93–102. https://doi.org/10.1080/10253890.2018.1511698 (2019).
doi: 10.1080/10253890.2018.1511698
pubmed: 30369292
Zhou, J. Norepinephrine transporter inhibitors and their therapeutic potential. Drugs Fut. 29, 1235–1244 (2004).
doi: 10.1358/dof.2004.029.12.855246
Sommerauer, M. et al. Decreased noradrenaline transporter density in the motor cortex of Parkinson’s disease patients. Move. Disord. 33, 1006–1010. https://doi.org/10.1002/mds.27411 (2018).
doi: 10.1002/mds.27411
Ding, Y.-S. et al. PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S, S)-(11)CO-methylreboxetine and HRRT. Synapse 64, 30–38. https://doi.org/10.1002/syn.20696 (2010).
doi: 10.1002/syn.20696
pubmed: 19728366
pmcid: 3727644
de Stefano, N. et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch. Neurol. 58, 65–70. https://doi.org/10.1001/archneur.58.1.65 (2001).
doi: 10.1001/archneur.58.1.65
pubmed: 11176938
Hobart, J., Freeman, J. & Thompson, A. Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain 123(Pt 5), 1027–1040. https://doi.org/10.1093/brain/123.5.1027 (2000).
doi: 10.1093/brain/123.5.1027
pubmed: 10775547
Engström, M., Flensner, G., Landtblom, A.-M., Ek, A.-C. & Karlsson, T. Thalamo-striato-cortical determinants to fatigue in multiple sclerosis. Brain Behav. 3, 715–728. https://doi.org/10.1002/brb3.181 (2013).
doi: 10.1002/brb3.181
pubmed: 24363974
pmcid: 3868176
Veauthier, C., Hasselmann, H., Gold, S. M. & Paul, F. the berlin treatment algorithm recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigue. EPMA J. 7, 25. https://doi.org/10.1186/s13167-016-0073-3 (2016).
doi: 10.1186/s13167-016-0073-3
pubmed: 27904656
pmcid: 5121967
Feinstein, A., Magalhaes, S., Richard, J.-F., Audet, B. & Moore, C. The link between multiple sclerosis and depression. Nat. Rev. Neurol. 10, 507–517. https://doi.org/10.1038/nrneurol.2014.139 (2014).
doi: 10.1038/nrneurol.2014.139
pubmed: 25112509
Eyding, D. et al. Reboxetine for acute treatment of major depression. Systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ (Clinical research ed.) 341, c4737. 10.1136/bmj.c4737 (2010).
Solaro, C. et al. Duloxetine is effective in treating depression in multiple sclerosis patients. An open-label multicenter study. Clin. Neuropharmacol. 36, 114–116. https://doi.org/10.1097/WNF.0b013e3182996400 (2013).
doi: 10.1097/WNF.0b013e3182996400
pubmed: 23783007
Hesse, S. et al. The association between in vivo central noradrenaline transporter availability and trait impulsivity. Psychiat. Res. Neuroimaging 267, 9–14. https://doi.org/10.1016/j.pscychresns.2017.06.013 (2017).
doi: 10.1016/j.pscychresns.2017.06.013
Tully, K. & Bolshakov, V. Y. Emotional enhancement of memory: how norepinephrine enables synaptic plasticity. Mol. Brain 3, 15. https://doi.org/10.1186/1756-6606-3-15 (2010).
doi: 10.1186/1756-6606-3-15
pubmed: 20465834
pmcid: 2877027
Wengler, K., He, X., Abi-Dargham, A. & Horga, G. Reproducibility assessment of neuromelanin-sensitive magnetic resonance imaging protocols for region-of-interest and voxelwise analyses. NeuroImage 208, 116457. https://doi.org/10.1016/j.neuroimage.2019.116457 (2020).
doi: 10.1016/j.neuroimage.2019.116457
pubmed: 31841683
Dantzer, R., O’Connor, J. C., Freund, G. G., Johnson, R. W. & Kelley, K. W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9, 46–56. https://doi.org/10.1038/nrn2297 (2008).
doi: 10.1038/nrn2297
pubmed: 18073775
pmcid: 2919277
Poser, C. M. et al. New diagnostic criteria for multiple sclerosis. Guidelines for research protocols. Ann. Neurol. 13, 227–231. https://doi.org/10.1002/ana.410130302 (1983).
doi: 10.1002/ana.410130302
pubmed: 6847134
Polman, C. H. et al. Diagnostic criteria for multiple sclerosis. 2010 revisions to the McDonald criteria. Ann. Neurol. 69, 292–302. https://doi.org/10.1002/ana.22366 (2011).
doi: 10.1002/ana.22366
pubmed: 21387374
pmcid: 3084507
Beck, A. T. An inventory for measuring depression. Arch. Gen. Psychiat. 4, 561. https://doi.org/10.1001/archpsyc.1961.01710120031004 (1961).
doi: 10.1001/archpsyc.1961.01710120031004
pubmed: 13688369
Flachenecker, P. et al. "Fatigue" bei Multipler Sklerose. Entwicklung und Validierung des "Würzburger Erschöpfungsinventars bei MS". Nervenarzt 77, 165–174. https://doi.org/10.1007/s00115-005-1990-x (2006).
doi: 10.1001/archpsyc.1961.01710120031004
pubmed: 16160812
Kurtzke, J. F. Rating neurologic impairment in multiple sclerosis. An expanded disability status scale (EDSS). Neurology 33, 1444. https://doi.org/10.1212/WNL.33.11.1444 (1983).
doi: 10.1212/WNL.33.11.1444
pubmed: 6685237
Lin, K.-S. & Ding, Y.-S. Synthesis, enantiomeric resolution, and selective C-11 methylation of a highly selective radioligand for imaging the norepinephrine transporter with positron emission tomography. Chirality 16, 475–481. https://doi.org/10.1002/chir.20055 (2004).
doi: 10.1002/chir.20055
pubmed: 15236345
Ichise, M. et al. Linearized reference tissue parametric imaging methods. Application to [
doi: 10.1097/01.WCB.0000085441.37552.CA
Innis, R. B. et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metabol. 27, 1533–1539. https://doi.org/10.1038/sj.jcbfm.9600493 (2007).
doi: 10.1038/sj.jcbfm.9600493
Becker, G. A. et al. PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains. J. Nucl. Med. 54, 723–731. https://doi.org/10.2967/jnumed.112.107185 (2013).
doi: 10.2967/jnumed.112.107185
pubmed: 23471310
Schmidt, P. Dissertation: Bayesian inference for structured additive regression models for large-scale problems (Chapter 6.1). Universitätsbibliothek der Ludwig-Maximilians-Universität, München, Germany. https://edoc.ub.uni-muenchen.de/ (2017).